Search
Zenas Biopharma Inc
ZBIOAdd to Watchlist
28.000USD
+2.620+10.32%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.77BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+10.32%
5 Days
+28.44%
1 Month
+54.10%
6 Months
-22.89%
Year to Date
-22.89%
1 Year
+206.35%
Key Figures
25.490Open
28.955High
2.38MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
3.82%Turnover Ratio
25.380Prev. Close
25.480Low
56.52MTurnover
LossP/E Static
5.20P/B
0.00%Div Yield TTM
-78.63%ROA
44.60052wk High
1.41Volume Ratio
-156.99MNet Profit
62.38MShares
-9.0976EPS TTM
--Beta
-137.11%ROE
8.91052wk Low
13.69%Amplitude
100.00%Gross Margin
1.77BMarket Cap
8.65Reward/Risk
5.57%Risk Rate
TradingKey Stock Score of Zenas Biopharma Inc
Currency: USD Updated: 2026-07-01Key Insights
Zenas Biopharma Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 45 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 42.12.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zenas Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Zenas Biopharma Inc Highlights
StrengthsRisks
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.00M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 10.00M.
Undervalued
The company’s latest PE is -3.08, at a low 3-year percentile range.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.29K shares of this stock.
Analyst Rating
Based on
8
analysts
Strong Buy
Current Rating
42.125
Target Price
+65.98%
Upside Space
Zenas Biopharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Zenas Biopharma Inc Info
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
Ticker SymbolZBIO
CompanyZenas Biopharma Inc
CEOMoulder (Leon O)
Websitehttps://zenasbio.com/
Related Instruments
-0.64%
-0.05%
-0.23%
-1.64%
-2.41%
-2.95%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52269.200
+14.900 (+0.03%)
29649.000
-150.300 (-0.50%)
7473.600
-1.900 (-0.03%)
14790.000
-565.000 (-3.68%)
68484.000
-1001.000 (-1.44%)
6286.900
+11.500 (+0.18%)
68.014
+0.046 (+0.07%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4071.860
+41.090 (+1.02%)
FAQs
What is the current price of Zenas Biopharma Inc (ZBIO)?
The current price of Zenas Biopharma Inc (ZBIO) is 28.00.
What is the symbol of Zenas Biopharma Inc?
The ticker symbol of Zenas Biopharma Inc is ZBIO.
What is the 52-week high of Zenas Biopharma Inc?
The 52-week high of Zenas Biopharma Inc is 44.60.
What is the 52-week low of Zenas Biopharma Inc?
The 52-week low of Zenas Biopharma Inc is 8.91.
What is the market capitalization of Zenas Biopharma Inc?
The market capitalization of Zenas Biopharma Inc is 1.75B.
Is Zenas Biopharma Inc (ZBIO) currently rated as Buy, Hold, or Sell?
According to analysts, Zenas Biopharma Inc (ZBIO) has an overall rating of STRONG BUY, with a price target of 42.12.
What is the Earnings Per Share (EPS TTM) of Zenas Biopharma Inc (ZBIO)?
The Earnings Per Share (EPS TTM) of Zenas Biopharma Inc (ZBIO) is -8.44.